Multiplikator Forward P/S: MEI Pharma (MEIP)

Production optimization via outsourcing to contract manufacturing organizations is driving growth, as confirmed by the expected P/S value on the GURU.Markets chart, where 0.30 reflects today's metric value. The resilience of MEI Pharma, Inc. (MEIP) is based on a diverse range of hematology programs at various stages. High financial barriers to entry and patent protection for innovations create a robust moat against third-party players in the oncology sector.

MEI Pharma Inc - Rasio kapitalisasi marang dodolan sing dikarepake MEIP (periode 04.07.2022 - 13.11.2024)

Rincian metrik keuangan lan pasar MEI Pharma Corporation (MEIP)

- rega pasar lan target rega analis:

Bagan rega MEI Pharma|MEIP - Target konsensus

- indikator kapitalisasi bursa perusahaan:

Kapitalisasi pasar MEI Pharma Corporation|MEIP - Total Nilai Perusahaan

- statistik nilai buku emiten:

Nilai Buku saben Saham MEI Pharma|MEIP - Pambiji Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih meipharma.com|MEIP - Nilai Agregat Aset

- data utang lan likuiditas:

- rincian asil keuangan lan kelipatan valuasi:

MEIP - Penghasilan resik|Proyeksi bathi mangsa ngarep MEI Pharma, Inc.|MEIP - Pangali P/E|Prakiraan rega marang bathi MEI Pharma Corp|MEIP - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA MEI Pharma Corporation|MEIP - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan MEI Pharma|MEIP - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan meipharma.com|MEIP - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep MEI Pharma, Inc.

- indikator volume dodolan lan pendapatan:

MEIP - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan MEI Pharma|MEIP - Kapitalisasi marang pendapatan|Multiplikator Forward P/S MEI Pharma Corporation

Ringkesan analisis perusahaan:MEI Pharma MEIP

For MEI Pharma, Inc. (MEIP), this indicator correlates market capitalization with projected revenue, determining the premium for future growth amid high risks of clinical failures. An analysis of the forward P/S multiple allows for an assessment of the company's valuation resilience against potential liquidity depletion, where inflated values signal a critical dependence of the share price on the success of oncology drug development.

Pesaing MEI Pharma, Inc.

Rasio rega marang prakiraan pendapatan TG Therapeutics TGTX|ACLX - Multiplikator forward rega marang pendapatan|Disc Medicine Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Syndax Corp|KURA: Multiplikator Forward P/S|ADCT - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan FHTX|VOR: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Nkarta, Inc. (NKTX)|COEP: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ATNM (Actinium Pharmaceuticals)|Rega forward marang dodolan ESLA|CASI Pharmaceuticals, Inc - Multiplikator Forward P/S|MRKR - Multiplikator Forward P/S|IN8bio, Inc (INAB) - Rasio rega marang prakiraan pendapatan|Eterna Therapeutics Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan GT Biopharma, Inc.|Multiplikator forward rega marang pendapatan Aptose (APTO)|Multiplikator Forward P/S BPTH|Multiplikator Forward P/S vincerx.com (VINC)